Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors


1 Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology, University of Bologna, Bellaria Hospital, Bologna, Italy

2 COMT – Centre for Molecular Translational Oncology Department of Life Sciences, University of Parma, Parma, Italy

3 Department of Life Sciences, Division of Genetics and Environmental Biotechnology, University of Parma, Parma, Italy

4 Department of Pathology and Laboratory Medicine, University of Parma, Parma, Italy

5 S.O.C. of Experimental Oncology 2, The National Tumour Institute Aviano – CRO-IRCCS, Aviano, Pordenone, Italy

6 Maxillofacial Surgery Section, Head and Neck Department, University of Parma, Parma, Italy

7 Unit of Maxillo-Facial Surgery, Department of Oral Sciences, University of Bologna, Bellaria Hospital, Bologna, Italy

8 Department of Biomedical and Neuromotor Sciences, Unit of Maxillo-Facial Surgery, University of Bologna, S. Orsola Hospital, Bologna, Italy

9 Unit of Maxillo-facial Surgery at Bellaria Hospital, Bologna, Italy

10 Unit of Maxillo-facial Surgery, “Casa Sollievo della Sofferenza”, San Giovanni in Rotondo, Italy